The White House said CDC and ACIP would realign the childhood vaccine schedule with peer countries. After EO 14420 §1 cited delay over ACIP’s composition, the President declared the schedule himself
A December 5, 2025 presidential memorandum told HHS and CDC to study peer-country childhood immunization practices and, if those practices were superior, update the U.S. schedule while preserving access. EO 14407 §2(c) (May 29, 2026) locked no-cost-sharing coverage for any ACIP/CDC category; EO 14420 does not repeal that lock. EO 14420 §1 (August 10, 2026) cited delay due to litigation over ACIP’s composition — no case is named here — then §2(a)(i) declared an 11-disease universal list, with hepatitis A and hepatitis B in both §2(a)(ii) and §2(a)(iii).
The White House said CDC and ACIP would realign the childhood vaccine schedule with peer countries. After EO 14420 §1 cited delay over ACIP’s composition, the President declared the schedule himself
A December 5, 2025 presidential memorandum told HHS and CDC to study peer-country childhood immunization practices and, if those practices were superior, update the U.S. schedule while preserving access. EO 14407 §2(c) (May 29, 2026) locked no-cost-sharing coverage for any ACIP/CDC category; EO 14420 does not repeal that lock. EO 14420 §1 (August 10, 2026) cited delay due to litigation over ACIP’s composition — no case is named here — then §2(a)(i) declared an 11-disease universal list, with hepatitis A and hepatitis B in both §2(a)(ii) and §2(a)(iii).
Log entry. Event date 2026-08-10. Instruments: Presidential Memorandum of December 5, 2025; Executive Orders 14212, 14407, and 14420; HHS request for information of August 21, 2026. Institutions: White House; HHS; CDC; ACIP; Departments of Justice and Education; states, as addressees of school-entry advice.
This is a process story. It is not a story that “vaccines were banned,” and it does not decide whether any vaccine is safe or unsafe.
December 5, 2025: a presidential memorandum told HHS and CDC to compare peer childhood schedules and, if those practices were superior, update the U.S. list while preserving access. It stated that the United States recommended “18 diseases, including COVID-19,” versus Denmark 10, Japan 14, and Germany 15 — the memorandum’s own comparisons; foreign schedules were not separately retrieved. May 29, 2026: EO 14407 (91 FR 33575) routed the update through CDC and ACIP. Section 2(c) locked no-cost-sharing coverage for immunizations in any ACIP/CDC category (private insurance, Medicaid, CHIP, Vaccines for Children). August 10, 2026: EO 14420 §1 said implementation “has been delayed due to litigation over the composition of the Advisory Committee on Immunization Practices and separate updates to the Federal vaccine schedule.” That is the instrument’s explanation. This desk names no case and no court. Section 2(a) then declared a three-category list. EO 14420 does not repeal EO 14407 §2(c).
The stated case
The government’s strongest fair explanation, taken from the instruments and the August 10 fact sheet, is that the United States was an outlier; that shots remain available and covered under the May lock; and that the President acted because, as EO 14420 §1 states, prior directives had been delayed.
The December memorandum frames the project as alignment with “best, scientifically-supported medical advice” and as an update only if HHS and CDC find peer practice superior, “while preserving access.” EO 14407 §2(b)–(c) keeps ACIP/CDC as the schedule writers and locks coverage. EO 14420 repeats the access line and adds that “Federal programs and funding should support maximal parental choice over childhood vaccines.” It does not repeal §2(c) of EO 14407.
The August 10 fact sheet, a White House characterization, says the order recommends immunizations “for 11 diseases – a decrease from the 18 diseases recommended by the Centers for Disease Control and Prevention in 2024,” with the rest moved to shared clinical decision-making. The May coverage lock remains the coverage instrument. The Administration’s §1 sentence is the fair statement of its case: delay, then “further action.”
Read charitably, August is a bypass of a stalled committee, not a ban.
What the record shows
February 13, 2025. EO 14212 established the MAHA Commission. Assessment/strategy PDFs were not retrieved.
December 5, 2025. Memorandum: 18 (U.S., including COVID-19) versus 10 / 14 / 15 (Denmark / Japan / Germany), as stated there. Update if HHS/CDC determine superiority; preserve access.
January 5, 2026 HHS press release. The listed URL returned HTTP 403 from this environment. It is not used as a retrieved source. Any claim that lives only on that page stays out of the lead.
May 29, 2026. EO 14407, 91 FR 33575. Section 2(b): CDC and ACIP “shall review” the scientific assessment “and, to the extent permitted by law, take any appropriate steps to update.” Section 2(c): coverage without cost sharing for all immunizations in any ACIP/CDC category. HHS Intergovernmental Affairs to inform state officials. The order describes an HHS scientific assessment this desk has not retrieved as a PDF.
August 10, 2026. EO 14420, later 91 FR 53173, FR Doc. 2026-16730. Section 1 is the delay clause, quoted above. Section 2(a) then declares three categories:
- §2(a)(i) all children: measles, mumps, rubella, diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type B, pneumococcal disease, human papillomavirus, and varicella (eleven diseases);
- §2(a)(ii) high-risk groups or populations: respiratory syncytial virus monoclonal antibodies, hepatitis A, hepatitis B, meningococcal B, meningococcal ACWY, and dengue;
- §2(a)(iii) shared clinical decision-making: hepatitis A, hepatitis B, rotavirus, meningococcal disease, influenza, and COVID-19.
Hepatitis A and hepatitis B appear in both §2(a)(ii) and §2(a)(iii). That is the text. This desk does not silently “fix” the overlap. EO 14420 does not repeal EO 14407 §2(c).
The same order says the combined MMR vaccine “should be administered in three separate single-disease shots once such products are domestically available,” and that, “to the maximum extent feasible, all childhood immunizations should be administered at separate medical visits.” Section 3 still “guarantee[s] continued availability of combination vaccines.” States and territories “are advised to review” the recommendations “and consider updating relevant laws and regulations that define the scope of immunization requirements for contexts such as school enrollment and attendance.” The Attorney General “shall take appropriate measures to further meritorious legal actions challenging State laws that conflict with” parental authority, religious freedom, disability accommodations, and equal protection, “including, to the extent applicable under Federal law, States’ obligations to provide religious and medical exemptions.” Justice, Education, and HHS are told to police contractors and grantees on the same list.
August 10 fact sheet. Characterizes “11” versus “18.” Separately, it attributes to the HHS assessment a 1980-to-2024 comparison: “at least 84 vaccine doses in at least 57 shots for 17 diseases, plus the RSV monoclonal antibody immunization for a total of 18 diseases.” Those 84-dose and 57-shot figures are fact-sheet characterizations of an HHS assessment this desk did not retrieve. They are not independently counted here. The same paragraph contains a White House “18” and an HHS-attributed “17” plus RSV. The discrepancy is flagged, not papered over.
August 21, 2026. An HHS press release announces a request for information on recommendation categories and shared clinical decision-making, stating that the RFI “advances” EO 14420. This desk opened that HHS page. It did not retrieve the Federal Register RFI text itself.
The contradiction
They said, in December: HHS and CDC will study peers and update if those practices are superior, while preserving access.
They said, in May: CDC and ACIP shall review and take appropriate steps; EO 14407 §2(c) continues coverage for any ACIP/CDC category.
They said, in August, in EO 14420 §1: that path “has been delayed due to litigation over the composition of” ACIP; therefore §2(a)(i) declares an 11-disease universal list, advises states on school-entry laws, and points the Attorney General at meritorious suits.
The record shows a change in who writes the federal list. December and May assigned the update to HHS/CDC/ACIP. August assigns a declared schedule to the President, then tells agencies to “advance” it. The §2(c) coverage lock is still on the May order; August does not repeal it. The new pieces are authorship and the state-law commands.
This is not a finding that access has ended. It is not a finding about any lawsuit. Section 1 is the only delay statement used here. It is a comparison of successive instruments.
What we know / What we do not know
Verified fact. The December memorandum’s 18 / 10 / 14 / 15 comparison; EO 14407 §2(c) coverage lock; EO 14420 §1 delay clause; §2(a)(i) 11-disease list; and the school-entry and DOJ sentences exist as retrieved. EO 14420 does not repeal §2(c).
Verified fact. Hepatitis A and hepatitis B are listed in both EO 14420 §2(a)(ii) and §2(a)(iii).
Attributed characterization. “11 versus 18,” and the 84-dose / 57-shot figures, are White House fact-sheet characterizations. The 17-versus-18 split appears inside that same sheet.
Analysis. If preserving access is the justification, the August order’s new work is who writes the schedule and whether DOJ will spend time against state school-entry laws.
What we did not retrieve. The HHS scientific-assessment PDF; any O’Neill or similar decision memo; MAHA assessment and strategy PDFs; the January 5, 2026 HHS press release (HTTP 403 from this environment). Independent fact-check HOLD: this desk does not name an ACIP case, caption, or court.
Evidence ledger
- WH2-C01 (verified fact). December 5, 2025 memorandum: U.S. “18 diseases, including COVID-19,” versus Denmark 10, Japan 14, Germany 15, as stated there; update if HHS/CDC determine superiority; preserve access. Source: White House memorandum.
- WH2-C02 (verified fact). EO 14407, May 29, 2026, 91 FR 33575, FR Doc. 2026-11180: §2(b) CDC/ACIP shall review and take appropriate steps; §2(c) coverage without cost sharing for any ACIP/CDC category (private insurance, Medicaid, CHIP, VFC). Sources: White House; Federal Register.
- WH2-C03 (verified fact). EO 14420, August 10, 2026, 91 FR 53173, FR Doc. 2026-16730: §1 delay “due to litigation over the composition of” ACIP “and separate updates” (no case named); §2(a)(i) 11-disease list; hepatitis A and hepatitis B in both §2(a)(ii) and §2(a)(iii); split MMR once domestically available; combination vaccines remain available under §3; states advised on school-entry laws; AG to further meritorious actions, including religious and medical exemptions to the extent applicable under federal law. EO 14420 does not repeal EO 14407 §2(c). Sources: White House; Federal Register.
- WH2-C04 (attributed allegation / characterization). Fact sheet “11” versus “18,” and “84 vaccine doses in at least 57 shots for 17 diseases, plus” RSV “for a total of 18.” Not independently counted. Source: White House fact sheet, August 10, 2026.
- WH2-C05 (verified fact). HHS announced an RFI on August 21, 2026, on recommendation categories and shared clinical decision-making, stating it advances EO 14420. Source: HHS press release.
- WH2-C06 (analysis). The August instrument changes the author of the federal childhood list from ACIP/CDC (May) to a presidential declaration (August), while repeating access language.
- WH2-C07 (unresolved question). Whether any lawsuit delayed ACIP, and how states will treat school-entry advice, are not established by the orders alone. No case is named.
Response from subjects
White House fact sheets are the on-record characterization. No individual right-of-reply was sought. These are policy instruments, not personal allegations. The January 5 HHS release could not be opened (HTTP 403); that gap is disclosed rather than filled from secondary write-ups.
Methodology note and update history
Fact-check identifier: fc-2026-08-30-open-source (independent check in; PASS on instruments unchanged; HOLD on naming an ACIP case). Medical safety is not adjudicated. First published 2026-08-30. High-risk entry because the subject is childhood immunization policy and state school-entry law. Update history: initial publication; 2026-08-30 wording lock — §1 / §2(a)(i) / §2(c) cites; hepatitis A and B in both (ii) and (iii); 14420 does not repeal 14407 §2(c).
Conclusion
December asked HHS and CDC to decide whether peers were superior. May told ACIP and CDC to update and, in §2(c), locked coverage. August §1 cited delay, then the President wrote the §2(a)(i) list and pointed DOJ at state school-entry laws. The May coverage lock remains. The fair government line remains available. So does the test: if access was never the dispute, the August novelty is authorship and the state-law turn.